Schaeffer Center co-directors Erin Trish and Dana Goldman argue that lawmakers are routing funds away from Medicare Part D drug reform to push through the new infrastructure bill.
Other featured articles
Leveraging Rapid Antigen Tests in School-Aged Children
To keep schools safe, students enrolled at LAUSD schools were required to show a negative COVID-19 test in the two weeks prior to the first day. Is this a good use of scarce resources?
After Their Initial Diagnosis, Many Adult COVID-19 Patients Continue Seeking Medical Care for up to Six Months or More
Analyzing claims data, does COVID-19 related healthcare utilization persist in for 180 days or more, also known as long COVID, after their initial diagnosis?
A Framework for Categorizing and Analyzing Prescription Drug Pricing Reform Options
Schaeffer Initiative experts present a framework for categorizing and analyzing a wide range of proposed policy reforms for prescription drug pricing.
Government Regulated or Negotiated Drug Prices: Key Design Considerations
Americans pay much higher prices for brand drugs than do people who live in other industrialized nations. Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost. With 70 percent of Americans reporting that lowering drug costs is their highest healthcare priority, the Congress and the Biden Administration are considering how to lower US drug prices